Inappropriate prescribing according to the STOPP/ START criteria in older people from a primary care setting
|
|
- Jade Bailey
- 6 years ago
- Views:
Transcription
1 The European Journal of General Practice ISSN: (Print) (Online) Journal homepage: Inappropriate prescribing according to the STOPP/ START criteria in older people from a primary care setting Alicia Castillo-Páramo, Ana Clavería, Asunción Verdejo González, Isabel Rey Gómez-Serranillos, M Carmen Fernández-Merino & Adolfo Figueiras To cite this article: Alicia Castillo-Páramo, Ana Clavería, Asunción Verdejo González, Isabel Rey Gómez-Serranillos, M Carmen Fernández-Merino & Adolfo Figueiras (2014) Inappropriate prescribing according to the STOPP/START criteria in older people from a primary care setting, The European Journal of General Practice, 20:4, , DOI: / To link to this article: Published online: 04 Apr Submit your article to this journal Article views: 703 View related articles View Crossmark data Citing articles: 10 View citing articles Full Terms & Conditions of access and use can be found at
2 European Journal of General Practice, 2014; 20: Original Article Inappropriate prescribing according to the STOPP/START criteria in older people from a primary care setting Alicia Castillo-Páramo1, Ana Clavería2, Asunción Verdejo González1, Isabel Rey Gómez-Serranillos1, M Carmen Fernández-Merino3 & Adolfo Figueiras4,5 1 Vigo Primary Care Region, Galician Health Service, Vigo, Spain, 2 Quality and Research Unit, Vigo Primary Care Region, Galician Health Service, Vigo, Spain, 3 Santiago Primary Region, Galician Health Service, Santiago de Compostela, Spain, 4 Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain, and 5 Consortium for Biomedical Research in Epidemiology & Public Health, Santiago de Compostela, Spain KEY MESSAGES: The higher the number of prescriptions, the greater the risk of potentially inappropriate medication according to STOPP/START criteria. Omission of a prescription is more likely in patients with multimorbidity or with a higher number of prescriptions. Of 87 STOPP/START criteria, 20 account for 80% of potentially inappropriate medication. ABSTRACT Background: STOPP (screening tool of older persons prescriptions)/start (screening tool to alert doctors to right treatment) criteria aim to identify potentially inappropriate medication (PIM) due to mis-, over- and under-prescription in older patients. Initially developed by Irish experts, their applicability has been demonstrated in primary health care (PHC). Objective: To quantify and identify the most frequent PIM at PHC level using STOPP/START criteria. To identify factors that may modulate the onset of PIM. Methods: Audit of a random sample of 272 electronic health records (including prescription, diagnosis and laboratory results) of patients 65 years old, with at least one prescription in the last three months, from a PHC setting in the Vigo Health Authority (Spain). Original STOPP/START criteria were used, as well as a version adapted to Spanish PHC. Descriptive statistics and generalized linear models were applied. Results: The median number of medicines per patient was 5 (inter-quartile range: 3 7). The prevalence of PIM identified by the STOPP criteria was 37.5% and 50.7%, with the original criteria and the Spanish version, respectively. Using both versions of the START tool, the prevalence of under-prescription was 45.9% and 43.0%, respectively. A significant correlation was found between the number of STOPP PIM and number of prescriptions, and between the number of START PIM with Charlson comorbidity index and number of prescriptions. Of 87 criteria, 20 accounted for 80% of PIM. Conclusion: According to STOPP/START criteria, there is a high level of PIM in PHC setting. To prevent PIM occurring, action must be taken. Keywords: Inappropriate prescribing, aged, primary health care, STOPP/START criteria, patient safety INTRODUCTION Appropriate drug prescription for the elderly is essential for their safety. The World Health Organization has included adverse drug reactions (ADRs) among the 10 most important causes of death in the world, and a recent systematic review estimated the prevalence of ADRs to be 16.1% (1). In Spain, a nationwide multicentre study in primary health care (PHC) concluded that 48% of ADRs were drug-related problems of which 58% were avoidable (2). Various factors contribute to the occurrence of ADRs among the elderly: higher morbidity and higher prevalence of chronic diseases, with the consequently higher number of simultaneous drug therapies and greater Correspondence: Alicia Castillo P á ramo, Camelias 85 2 B 36211, Vigo (Pontevedra), Spain. aliciacastilloparamo@gmail.com (Received 17 March 2013; revised 21 January 2014; accepted 9 February 2014 ) ISSN print/issn online 2014 Informa Healthcare DOI: /
3 282 A. Castillo-P á ramo et al. probability of drug interactions; age-related physiological changes, which alter the metabolism of some drugs making them more susceptible to causing side effects; and the very limited presence of this age group in clinical trials (3). Like the UK National Health Service, the Spanish public health care system has free universal coverage. It is decentralized into 17 Autonomous Communities. In the Autonomous Community of Galicia, the Servizo Galego de Sa ú de (Galician Health Service) serves inhabitants with 398 health centres and 3141 general practitioners (GPs). It is organized into seven health authorities, each one a geographical and administrative entity. The electronic health record (EHR) is common to both PHC and hospital settings and it records all information regarding diagnoses, diagnostic tests, hospital reports and prescriptions. All healthcare professionals have access to EHR, and 98% of the prescribing/dispensing is electronic. Everyone has an assigned GP, who acts as gatekeeper. Therefore, the GP, who is responsible for renewing prescription of chronic medications, is in the ideal position to understand and act amid the complexity of prescribing for older patients. Subsequently, there is considerable interest about potentially inappropriate prescription at this level of care. Inappropriate prescribing can be defined as a situation in which the pharmacotherapy does not meet accepted medical standards and it may include under-, over- and mis-prescribing (4). In the international literature, the most common tools for detecting potential inappropriate medication (PIM) use explicit based criteria established by expert consensus, followed by clinical judgment. Although, they require regular updating and local adaptation due to differences in the availability of medication and the prescribing patterns between countries, their greater inter-rater reliability and improved application time allow these criteria to be implemented with relative ease into daily clinical practice (4,5). Among such criteria, the most popular is the American Beers criteria (6). Some studies have highlighted limitations regarding the applicability of the Beers criteria in a European context (7). This was one of the main reasons why in 2008 Gallagher et al., proposed a new set of explicit criteria: STOPP (screening tool of older persons prescriptions)/start (screening tool to alert doctors to right treatment) (8). These are European criteria, organized according to physiological systems and can quickly be applied in routine daily practice. The criteria are very sensitive in identifying potentially inappropriate medications and drug-induced harm, and also address the issue of under-prescribing potentially beneficial medications (9). These criteria have already been applied successfully in various clinical scenarios, including PHC (10,11). Our research group has assessed the suitability of the criteria at this level of care using the RAND methodology and has proposed a modification (the AP2012 version) (12). To identify the most common PIM, is the first step in preventing adverse events. We, therefore, decided (a) to quantify the PIM in PHC within our health authority and to analyse the criteria that account for the highest proportion of inappropriate prescribing; and (b) to identify the patient variables that may influence its occurrence. METHODS Study design and setting An observational cross-sectional study was designed using an audit of EHR. The study was carried out at the PHC level within our health authority, which includes 53 health centres and 364 GPs. In 2011 the population served was inhabitants (21.3% 65 years). Inclusion and exclusion criteria For the audit, all patients 65 years of age, with at least one daily medication prescribed in the three months prior to the start of the study, were included. In addition, those who had died in the last three months, patients living in nursing homes and terminally ill patients were excluded. Data collection and definition of variables Two members of the research team using Excel carried out information extraction. If the EHR appeared to be incomplete, the paper clinical record was checked. When there was uncertainty about the interpretation of a criterion, the rest of the team was consulted. Data collection was carried out from June 2011 to October Audit quality control was assessed by inter-observer concordance. The Kappa value for positive agreement of the STOPP criteria was 0.82 (95% CI: ), and 0.84 (95% CI: %) for the START ones. The variables considered were sex, age, diagnosis (coded with the International Classification for Primary Care, ICPC-2) and current medications (encoded with the Anatomical Therapeutic Chemical classification system); the Charlson Comorbidity Index (CCI) was calculated and also included as a variable (13 15). Assessment of potentially inappropriate prescribing Potentially inappropriate prescribing was assessed using the START/STOPP criteria, translated by Delgado et al., for Spain, as well as the AP2012 version (8,12,16). In this modified version, the criteria excluded were Bisphosphonates in patients receiving maintenance doses of oral
4 STOPP/START criteria in primary health care 283 corticosteroids and Antiplatelets in diabetes mellitus (DM) if one or more major cardiovascular risk (CV) factors coexist. The criterion Use of proton-pump inhibitors (PPI) outside their approved indications was included, and those criteria that only referred to warfarin were modified by adding acenocumarol, which is more commonly used in Spain. Outcome variables Outcome variables were: (a) Ratio of patients with at least one PIM according to STOPP or START criteria; (b) Number of PIM identified with STOPP or START criteria. These variables were assessed using the original STOPP/START criteria as well as the Spanish AP2012 version described earlier (8, 12). Sample size For a population of , 65 years old, with an expected PIM prevalence of 23.0%, precision of 5% and a 95% confidence interval (CI), 272 EHR had to be reviewed (10). Records were selected by simple randomized sampling with replenishment between the total number of patients 65 years served by the Servizo Galego de Sa ú de. A computer technician from outside the research team used Microsoft Excel 2003 to calculate the random numbers. To establish inter-observer consistency, a sample of 31 patients was used, calculated for a sample size of n 272, with an expected agreement of 90%, an interval equal to 10 and a 95% confidence interval (17). Statistical analysis Descriptive statistics included the ratio and standard deviation (SD), and the median and interquartile range (IQR) for non-parametric variables. Differences in distributions of categorical variables were compared using the Chi-squared or Fisher s exact tests. The distribution of continuous variables was assessed by the Kolmogorov Smirnov test. The Mann Whitney test was used to determine independence of two non-parametric variables. To calculate relative risks (RR) of PIM and adjusted CI for each set of criteria, with number of STOPP PIM and number of START PIM per patient as outcome, generalized linear models (GLM) were applied. As the response variable is a count variable, it would be logical to use models with Poisson response, however, the variance of the variable is greater than the mean (over dispersion). Therefore, to obtain standard errors corrected for overdispersion parameters, models with a Poisson response were replaced by negative binomial response models. The R statistical software (version ) was used for the estimation of the function of the GLMs. For the construction of the GLM model, initially a bivariate analysis was carried out with exposure variables and potential confounders. Subsequently, a multivariate analysis was undertaken including those independent variables that had a level of statistical significance lower than 0.2 in the bivariate analysis. In this model, the independent variables with a higher level of statistical significance were eliminated if they did not change the coefficients of the main variables of exposure by more than 10%, and if the Schwarz s Bayesian Information Criterion improved. All P values are two-sided, and the level of significance was set at P values of 0.05 or less. Finally, the Pareto diagram was used to establish criteria that cover the highest weight of non-compliance with the prescription, presenting those that represent 80% of the PIM for each type of criterion and version. Ethical considerations A unique identification number was allocated to each patient to ensure confidentiality. The study was approved by the Ethical Committee for Clinical Investigation of Galicia (Cod. 2010/390). RESULTS A total of 65 medical records were excluded (48 without prescriptions, 7 deceased, 7 institutionalized, 3 terminal). The study population included 60.6% (95% CI: ) women and 39.3% (95% CI: ) men. The median age was 76.0 (IQR: 71 81) years old and the median number of prescriptions per patient was 5 (IQR: 3 7). The median CCI was 1 (IQR: 0 2). The prevalence of mis- and over-prescribing using the original criteria was 37.5% (95% CI: ), and 50.7% (95% CI: ) using the Spanish AP2012 version. The prevalence of under-prescribing was 45.9% (95% CI: ) with the original criteria, and 43.0% (95% CI: ) with the AP2012 version. In Tables 1 and 2, patients demographics and descriptive analysis are described in more detail. No significant differences in prevalence were found when applying each STOPP/START version. For both sets and versions of criteria, in the bivariate analysis, statistically significant differences were found between: (a) sex and age or CCI; (b) STOPP PIM and age or number of prescriptions; and (c) START PIM and age, number of STOPP criteria, CCI and number of prescriptions (Figure 1). The relationship between STOPP PIM and number of prescriptions was statistically significant using a GLM with both tools (original and Spanish AP2012 version). For START PIM the relationships with age and the
5 284 A. Castillo-P á ramo et al. Table 1. Patients demographics. Median (IQR ) Total Men Women Age 76.0 ( ) 75.0 (70 81) 77.0 ( ) Charlson comorbidity index 1.0 (0 2) 2.0 (0 1.3) 1.0 (0 2.0) No. of prescriptions 5.0 (3 7) 5.0 (3 7) 5.0 ( ) number of prescriptions were statistically significant as was that with CCI, but to a lesser extent. The cut-off points are identified and shown in Table 3 (CCI 2 and number of prescriptions 6). The most prevalent STOPP and START criteria of the two versions are compared (Table 4), with just 20 of 87 criteria representing the 80th PIM percentile. The most prevalent are STOPPGI6 (PPI not indicated), STARTMS3 (Calcium and Vitamin D supplement in patients with osteoporosis) and STARTEN3 (Antiplatelet therapy in DM with co-existing major CV risk factors). within our health authority varied, depending on the version used, between 37.5% and 50.7% for STOPP PIM and between 42.6% and 45.9% for START PIM. The main difference between the original criteria and those adapted to PHC is marked by the inclusion of Use of proton-pump inhibitors (PPI) outside their approved indications with a prevalence of 25%, and the exclusion of Antiplatelet in DM if one or more major CVDR factors coexist with a prevalence of 9.9% when applying the original criteria, considered being an obsolete criterion in the AP2012 version (12). DISCUSSION Main findings The STOPP/START criteria constitute an easy to use tool for the detection of PIM. The prevalence found in PHC Strengths and limitations The main limitations of the study stem from the use of EHR, because over-the-counter medication is not included, compliance is not assessed, incomplete records may exist, and the quality of the information contained Table 2. Descriptive analysis. Comparison of criteria ratio by version Gallagher (8) AP2012 (12) STOPP ratio % (95% CI) 37.5 ( ) 50.7 ( ) START ratio % (95% CI) 45.9 ( ) 43.0 ( ) No. of STOPP criteria per patient Total % 28.3% % 18.7% 3 1.1% 2.5% 4 0.7% 0.3% 5 0.3% 0.7% 6 0.0% 0.0% No. of START criteria per patient Total % 24.6% % 12.1% 3 6.2% 3.6% 4 1.4% 2.2% 5 0.7% 0.0% 6 0.3% 0.3% Comparison by version and by physiological system Gallagher (8) AP2012 (12) System STOPP START STOPP START Cardiovascular 13.9% 30.8% 13.9% 30.8% Central nervous 8.4% 5.1% 8.4% 5.1% Gastrointestinal 4.4% 1.8% 29.4% 1.8% Respiratory 0.7% 6.6% 0.7% 6.6% Musculoskeletal 11.0% 13.2% 11.0% 12.5% Urogenital 2.9% 2.9% Endocrine 1.1% 23.9% 1.1% 13.9% Fall 1.8% 1.8% Analgesic 1.1% 1.1% Duplicate 8.0% 8.0%
6 STOPP/START criteria in primary health care 285 Figure 1. Original STOPP/START by sex, Charlson index and number of prescriptions. in the EHR is not quantitatively evaluated by the Servizo Galego de Sa ú de. The quality of administrative data depends on the gaps in clinical information, coding procedures, and the billing context. Despite the inter-observer concordance that is in agreement with that observed in research in other countries, interpreting certain criteria were difficult (17 19). For example, when a patient with type 2 DM without renal failure and intolerance to metformin strictly would fail the criterion, but may need or be given another treatment; or for those START criteria relating to higher cardiovascular risk due to the use of antiplatelets or statins, in which the American Diabetes Association recommends secondary prevention strategies (20). Hence, although not a major risk factor, having suffered a prior heart failure or stroke should be incorporated into the Table 3. Multivariate regression model. Gallagher (8) AP2012 (12) Model GLM binomial negative Model GLM binomial negative Outcome No. STOPP PIM Outcome No. STOPP PIM Variables (RR & 95% CI) Variables (RR & 95% CI) (Intercept) ( )a (Intercept) ( )a CCI ( ) CCI ( ) No. of prescriptions 3 to ( ) b No. of prescriptions 3 to ( )a No. of prescriptions ( ) a No. of prescriptions ( )a Outcome No. START PIM Outcome No. START PIM Variables (RR & 95% CI) Variables (RR & 95% CI) (Intercept) ( )b (Intercept) ( )a Age ( ) d Age ( )c CCI ( ) CCI ( )d CCI ( )a CCI ( )a No. of prescriptions 3 to ( ) No. of prescriptions 3 to ( )c No. of prescriptions ( )b No. of prescriptions ( )b CCI, Charlson comorbidity index; PIM, potentially inappropriate medication; RR, relative risk. Significant codes: a P 0; b P 0.001; c P 0.01; d P 0.05.
7 286 A. Castillo-P á ramo et al. Table 4. Criteria representing 80% of the potentially inappropriate medication by version. Gallagher (8) AP2012 (12) Criteria % Relative frequency % Cumulative frequency % Relative frequency % Cumulative frequency STOPPGI6 PPI not indicated STARTMS3 Calcium and vitamin D supplement in patients with osteoporosis STARTEN3 Antiplatelet therapy in DM with co-existing major CV risk factors STOPPDU1 Duplicate drug classes STOPPMS4 Long-term use of NSAID ( 3 months) for symptom relief of mild osteoarthritis STARTEN4 Statin therapy in DM, if co-existing major CV risk factors STOPPCV13 ASA with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event STARTCV5 Statin therapy with history of coronary, cerebral or peripheral vascular disease, where the patient s functional status remains independent for activities of daily living and life expectancy is 5 years STARTEN1 Metformin with Type 2 DM metabolic syndrome (in the absence of renal impairment) STARTCV3 ASA or clopidogrel with a documented history of atherosclerotic coronary, cerebral or peripheral vascular disease in patients with sinus rhythm STARTRE1 Regular inhaled β 2 agonist or anticholinergic agent for mild to moderate asthma or COPD STARTCV1 Warfarin/acenocoumarol in the presence of AF STARTCN2 Antidepressant drug in the presence of moderate-severe depressive symptoms lasting at least 3 months STOPPGI4 PPI for peptic ulcer disease at full therapeutic dosage for 8 weeks STARTCV6 ACE inhibitor with chronic heart failure STARTCV7 ACE inhibitor following acute myocardial infarction STOPPCN7 Long term (i.e. 1 month), long-acting BDZ and BDZ with long-acting metabolites STARTCV2 ASA in the presence of AF, where warfarin/acenocoumarol is contraindicated, but not ASA STOPPCN8 Long term (i.e. 1 month) neuroleptics as long-term hypnotics PPI, proton pump inhibitor; DM, diabetes mellitus; CV, cardiovascular; NSAID, non-steroidal anti-inflammatory drug; ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; AF, chronic atrial fibrillation; ACE, angiotensin converting enzyme fibrillation; BDZ, benzodiazepines; CV, cardiovascular; CN, central nervous; GI, gastrointestinal; RE, respiratory; MS, musculoskeletal; EN, endocrine; DU, duplication. criteria. It is also difficult to interpret the use of a hypnotic or neuroleptic treatment in agitated patients with dementia without an assessment by the clinician. The criteria shown in Table 5 are those that generated conflict or controversy in interpretation at the time of the audit, and our team strongly suggests that these should be discussed and modified in the next version. The latest published evidence suggests new criteria that need to be agreed, such as adding zolpidem due to its association to fracture risk, or removing memantine associated with donepezil in moderate-severe Alzheimer s disease (21,22). Moreover, acetylsalicylic acid (ASA) should be replaced by recently commercialized anticoagulants (Rivaroxaban, apixaban, and dabigatran) in patients intolerant to acenocoumarol. In regard to the tool, the explicit criteria are reliable and easy to implement, but do not take into account the particularities of the health system (funding, co-payment) or the comorbidity of the patient (9,23). Therefore, clinical judgment is essential for each particular patient. Lertxundi et al., highlighted the need to adapt the criteria to the market of each country and take into account the commercial novelties (24). Therefore, the STOPP/START criteria have been adapted for use in specific countries (as in France), or to design their own lists (as in Norway, Germany and England), or guides (as in the Netherlands) (18,25 28). Comparison with existing literature A recent systematic review analyses PIM in PHC and estimates an average frequency of 19.1% (95% CI: %) in Europe (3). This review includes studies mainly carried out with the Beers criteria, although one uses the STOPP/START criteria, with STOPP and START prevalence of 21.4% and 22.7%, respectively (10). These values are lower than those reflected in this study. The differences may be due to the greater quantity of information recorded in the EHR in Servizo Galego de Sa ú de. ASA with cardiovascular risk was the most frequently omitted drug, followed by calcium and vitamin D supplements in
8 STOPP/START criteria in primary health care 287 Table 5. Controversial criteria. Criteria Discussion STOPPCV13: ASA with no history of coronary, cerebral or What happens if they have a treatment with triflusal or ticlopidin? a peripheral vascular symptoms or occlusive event STOPPRE3: Nebulized ipratropium with glaucoma What about tiotropium? a STOPPMS1-MS4, STOPPMS6, STOPPMS8: NSAIDs Could metamizole be considered? Not by the WHO (14) STOPPFA1: Benzodiazepines (sedative, may cause reduced Adding zolpidem, due to its association to fracture risk (21) sensorium, impair balance) STOPPCN8: Long-term (i.e. 1 month) neuroleptics as long-term What about the use of neuroleptics in dementia (37)? hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls) STOPPCN14 Memantine donepezil Removing memantine associated with donepezil in moderate-severe Alzheimer s disease (22) STARTCV1: Warfarin/acenocoumarol in the presence of AF A patient with AF that should be treated with an anticoagulant, but who is 83 years old, suffers from Alzheimer s disease and has a high risk of relapse: Would it be inappropriate not to prescribe a vitamin K antagonist? STARCV2: ASA in the presence of AF, where warfarin/ Recently commercialized anticoagulants should be added acenocoumarol is contraindicated, but not ASA (rivaroxaban, apixaban, and dabigatran) a in patients intolerant to acenocoumarol STARTCV3: ASA or clopidogrel with a documented history of What happens if they have a treatment with triflusal or ticlopidin? a atherosclerotic coronary, cerebral or peripheral vascular disease in patients with sinus rhythm STARTCV6: ACE inhibitor with chronic heart failure What if they are treated with ARBs? a STARTCV7: ACE inhibitor following acute myocardial infarction What if they are treated with ARBs? a STARTEN1: Metformin with Type 2 DM metabolic syndrome (in the absence of renal impairment) STARTEN3: Antiplatelet therapy in DM with co-existing major CV risk factors STARTEN4: Statin therapy in DM if co-existing major CV risk factors A patient with DM 2, without renal failure but with intolerance to metformin strictly fails the criterion, but may need or be given another treatment ADA also recommends secondary prevention strategies (20), therefore, having suffered a prior heart failure or stroke should be incorporated into the criteria ADA also recommends secondary prevention strategies (20), therefore, having suffered a prior heart failure or stroke should be incorporated into the criteria ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; AF, chronic atrial fibrillation; ACE, angiotensin converting enzyme fibrillation; ARBs, angiotensin receptor blockers; BDZ, benzodiazepines; CV, cardiovascular; CN, central nervous; FA, falls; RE, respiratory; MS, musculoskeletal; EN, endocrine; DU, duplication; DM, diabetes mellitus; ADA, American Diabetes Association. a European public assessment reports available at: pages/medicines/landing/epar search. jsp &mid WC0b01ac058001d124 osteoporosis, and statins in relation to the cardiovascular and endocrine system. Failure for the START criterion regarding calcium and vitamin D could be explained in patients with multiple comorbidities and medications, if such elements are provided in the diet. This coincides with our results. Another study conducted in Ireland recorded a STOPP prevalence of 36% in a PHC setting; the most prevalent criteria were PPI at the maximum dose over eight weeks, followed by NSAIDs for more than three months, long-acting benzodiazepines and duplicate prescriptions (11). In Spain, Conejos et al., applied STOPP/START criteria in comparison with Beers criteria and detected a higher PIM with STOPP in the three settings analysed (PHC, hospital, nursing home care), with significant differences found between them in the START criteria (29). Although using a convenience sample and eliminating some criteria, another study in PHC with the STOPP/START criteria detected 34.3% STOPP and 24.2% START prevalence, with results that were very similar to ours for the most common criteria (30). Ryan et al., correlated the over-prescribing type of PIM with the number of prescribed medications and age (10). Nevertheless, they did not correlate the number of prescriptions with the prevalence of omission criteria. In this study, a correlation was found using GLM, which could be explained by the restraint on expanding the number of drugs prescribed to a patient when they are already taking a large number. This would also explain the correlation between CCI and START PIM (31). Implications for practice and future research Results found, combined with the advantages in terms of easy application, make these criteria suitable for use in PHC practice, although the AP2012 version is more suitable for use, at least in Spain.
9 288 A. Castillo-P á ramo et al. Hence, it is essential that the criteria are updated regularly. However, usage cannot replace the judgement of the clinician, who considers the complete clinical and holistic picture of a patient. The criteria should serve as a guide for detecting those patients who need to change their prescription or who need to be incorporated into other drug safety controls. The STOPP/START criteria have been shown to reduce PIM in a clinical trial (32). The association between STOPP PIM and preventable ADRs has recently been demonstrated (33). In Spain, in older inpatients, 69% of ADRs have been reported to be related to PIM according to STOPP or Beers criteria, using the Naranjo algorithm (34). Future research should focus on involving a larger number of patients to confirm these results and analyse their clinical impact, such as software applications that alert clinicians or allow self-assessment (4,35,36). As in this study only a portion of the criteria represents 80% of the non-compliance cases, implementation of a shorter version using the most important parameters in our field to reduce application time is suggested. The intention is to carry out a study with a larger sample size in PHC to analyse the results obtained using this shorter version. Conclusion There are a high percentage of mis-, over- and underprescription in PHC settings. As expected for the 65 years old group, multimorbidity and a high number of prescriptions were related to the occurrence of PIM. The need to revise the STOPP/START criteria to fit the new evidence has been confirmed quantitatively as proposed in the AP2012 version, because 25% of patients have an inadequate PPI prescription, criteria are not covered in the original version. Moreover, 20 of 87 criteria account for 80% of PIM, therefore, are prioritized for use in training and/or quality improvement activities. FUNDING The study received a grant from the Spanish Ministry of Health and Consumer Affairs in public competition, reference number EC 10/172. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. REFERENCES 1. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: A systematic review. Ann Pharmacother ;45: APEAS study. Patient safety in primary health care. Madrid: Ministry of Health & Consumer Affairs ; Opondo D, Eslami S, Visscher S, De Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: A systematic review. PLoS ONE 2012 ;7:e Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SNS. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: A systematic review. J Am Geriatr Soc ;59: Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging 2010 ;27: Beers M. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med ; 151 : Fialová D, Topinková E, Gambassi G, Finne-Soveri H, Jónsson PV, Carpenter I, et al. Potentially inappropriate medication use among elderly home care patients in Europe. J Am Med Assoc ;293: Gallagher P, Ryan C, Byrne S, Kennedy J. STOPP (Screening tool of older person s prescriptions) and START (Screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther ;46: Lam MPS, Cheung BMY. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert Rev Clin Pharmacol ;5: Ryan C, O Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol ;68: Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: A national population study. Br J Clin Pharmacol ;69: Castillo-Páramo A, Pardo-Lopo R, Gómez-Serranillos IR, Verdejo-González A, Figueiras A. Assessment of the appropriateness of STOPP/START criteria in primary health care in Spain by the RAND method. SEMERGEN 2013 ;39: Spanish. Wonca. ICPC. International classification of primary care. Oxford: Oxford University Press ; WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment Oslo, WHO Collaborating Centre for Drug Statistics Methodology ; Charlson M, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis ;40: Delgado Silveira E, Muñoz García M, Montero Errasquin B, Sánchez Castellano C, Gallagher PF, Cruz-Jentoft AJ. Inappropriate prescription in older patients: The STOPP/START criteria. Rev Esp Geriatr Gerontol ;44: Spanish. Gallagher P, Baeyens JP, Topinkova E, Madlova P, Cherubini A, Gasperini B, et al. Inter-rater reliability of STOPP (screening tool of older persons prescriptions) and START (screening tool to alert doctors to right treatment) criteria amongst physicians in six European countries. Age ageing 2009 ;38: Lang P, Hasso Y, Belmin J, Payot I. STOPP-START: Adaptation of a French language screening tool for detecting inappropriate prescriptions in older people. Can J Public Health 2009 ; 100 : French. Hernández Perella JA, Mas Garriga X, Riera Cervera D, Quintanilla Castillo R, Gardini Campomanes K, Torrabadella Fàbregas J. Inappropriate prescribing of drugs in older people attending primary care health centres: Detection using STOPP-START criteria. Rev Esp Geriatr Gerontol ;48: Spanish. American Diabetes Association. Standards of medical care in diabetes Diabetes care 2012 ;35:S11 S63.
10 STOPP/START criteria in primary health care Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med ;8:1 6. Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. Br Med J ; 344 : e2986. Gavilán Moral E, Villafaina Barroso A, editors. Polypharmacy and health: Strategies for therapeutic appropriateness. Barcelona: Reprodisseny; Spanish. Available at com (accessed). Lertxundi U, Peral J, Hern á ndez R. Comments on the Spanish version of the STOPP/START criteria. Rev Esp Geriatr Gerontol ;46: Spanish. Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J. The Norwegian general practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care 2009 ;27: Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: The PRISCUS list. Dtsch Arztebl Intl ;107: Dreischulte T, Grant AM, McCowan C, McAnaw JJ, Guthrie B. Quality and safety of medication use in primary care: Consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clin Pharmacol ;12:5. Vermeulen Windsant-van den Tweel AM, Verduijn MM, Derijks HJ, van Marum RJ. Detection of inappropriate medication use in the elderly; will the STOPP and START criteria become the new Dutch standards? Ned Tijdschr Geneeskd ;156:A5076. Dutch. Conejos Miquel MD, S á nchez Cuervo M, Delgado Silveira E, Sevilla Machuca I, Gonz á lez-blazquez S, Montero Errasquin B, et al. Potentially inappropriate drug prescription in older subjects across health care settings. Eur Geriatr Med ; 1 : Candela Marroquin E, Mateos Iglesia N, Palomo Cobos L. Adequacy of medication in patients 65 years or older in teaching health centers in C á ceres, Spain. Rev Esp Salud P ú blica 2012 ; 86 : Spanish Schwarz G. Estimating the dimension of a model. Ann. Stat ;6: Gallagher PF, O Connor MN, O Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: A randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther ;89: Hamilton H, Gallagher P, Ryan C, Byrne S, O Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med ;171: Fernández-Regueiro R, Fonseca-Aizpuru E, López-Colina G, Álvarez-Uría A, Rodríguez-Ávila E, Morís-De-La-Tassa J. Inappropriate drug prescription and adverse drug effects in elderly patients. Rev Clin Esp ;211: Spanish. Martín Lesende I. Inappropriate prescribing in the elderly: Clinical tools beyond the simple assessment. Rev Esp Geriatr Gerontol ;46: Spanish. Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, et al. Audit and feedback: Effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev ;6: CD Fort I, Formiga F, Robles MJ, Regalado P, Rodríguez D, Barranco E. High prevalence of neuroleptic drug use in elderly people with dementia. Med Clin (Barc) ;134: Spanish.
Screening tools for elderly patients in primary care
Screening tools for elderly patients in primary care Cristín Ryan 1 Prof. Julia Kennedy 1 Dr. Denis O Mahony 2 Dr. Stephen Byrne 1 Co-Investigator: Dr. Paul Gallagher 2 1 Pharmaceutical Care Research Group,
More informationSTOPP and START criteria October 2011
# START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which
More informationSTOPP START Toolkit Supporting Medication Review in the Older Person
STOPP START Toolkit Supporting Medication Review in the Older Person STOPP: Screening Tool of Older People s potentially inappropriate Prescriptions START: Screening Tool to Alert doctors to Right (appropriate,
More informationPotentially Inappropriate Medications in Elderly Haemodialysis Patients Using the STOPP Criteria. Krystina Parker, Willy Aasebø & Knut Stavem
Potentially Inappropriate Medications in Elderly Haemodialysis Patients Using the STOPP Criteria Krystina Parker, Willy Aasebø & Knut Stavem Drugs - Real World Outcomes ISSN 2199-1154 Drugs - Real World
More informationCompleted audit cycle to explore the use of the STOPP/START toolkit to optimise medication in psychiatric in-patients with dementia
Completed audit cycle to explore the use of the STOPP/START toolkit to optimise medication in psychiatric in-patients with dementia Victor M. Aziz, Natalie Hill, Sugandha Kumar BJPsych Bulletin (08) 4,
More informationPublished in: International Journal of Clinical Pharmacy. Document Version: Publisher's PDF, also known as Version of record
Evaluating the prevalence of potentially inappropriate prescribing in older adults in intermediate care facilities: a cross-sectional observational study Millar, A., Hughes, C., & Ryan, C. (2017). Evaluating
More informationC. A. K. van der Stelt 1 A. M. A. Vermeulen Windsant-van den Tweel. A. C. G. Egberts 2,3 P. M. L. A. van den Bemt
Drug Saf (2016) 39:79 87 DOI 10.1007/s40264-015-0361-1 ORIGINAL RESEARCH ARTICLE The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients:
More informationThe PROMPT criteria: Development and validation of prescribing indicators in middle-aged adults
The PROMPT criteria: Development and validation of prescribing indicators in middle-aged adults Dr. Janine Cooper, Professor Carmel Hughes, Dr. Cristín Ryan, Professor Susan Smith, Dr. Emma Wallace, Dr.
More informationStronger together - optimizing pharmacotherapy on geriatric wards?
Stronger together - optimizing pharmacotherapy on geriatric wards? Clinicamp FOD 27/4/2018 Dr. Jean-Claude Lemper ( Geriater UZ Brussel) Apr. Julie Hias (ziekenhuisapotheker UZ Leuven) Project College
More informationASPIRIN MISUSE AT HOME ACCORDING TO START AND STOPP IN FRAIL OLDER PERSONS
ASPIRIN MISUSE AT HOME ACCORDING TO START AND STOPP IN FRAIL OLDER PERSONS O. Dalleur 1,4, B. Boland 2,3, A. Spinewine 4-5 1 Pharmacy and 2 Geriatric Medicine, St-Luc university Hospital, 3 Institute of
More informationAppropriateness of prescribing in older patients
Appropriateness of prescribing in older patients Which tools should be used? Anne Spinewine MPharm, MSc, PhD Université catholique de Louvain, Belgium Louvain Drug Research Institute and CHU Mont-Godinne
More informationConflict of interest declaration and sources of funding
Potentially Inappropriate Prescribing immediately prior to Long-Term Care admission (PIP in LTC): Validation of tools for their future use across Ontario Bruyère CLRI Webinar March 24 th, 2016 and Bruyère
More informationMedication safety in vulnerable patient groups - Elderly patients -
Woodennature/CC-BY-SA-3.0 http://theintelligence.de Medication safety in vulnerable patient groups - Elderly patients - 20th Congress of EAHP 25-27 March, 2015, Hamburg, Germany Dr. rer. nat. Beate Wickop
More informationThere s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients
There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients Marilyn N. Bulloch, PharmD, BCPS Assistant Clinical Professor
More informationThe Role of Pharmacists achieving international best practice standards and realising key opportunities.
The Role of Pharmacists achieving international best practice standards and realising key opportunities. Dr. Stephen Byrne Senior Lecturer in Clinical Pharmacy & Director of the MSc in Clinical Pharmacy
More informationDeconstructing Polypharmacy. Alan B. Douglass, M.D. Director
Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis
More informationAssociation between Potentially Inappropriate Prescription (PIP) and Health Outcome Among Geriatric Home Residents
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (6), Page 4660-4665 Association between Potentially Inappropriate Prescription (PIP) and Health Outcome Among Geriatric Home Residents Moatassem
More informationDisclosures. Use caution in the elderly: review of safe and effective medication use in older patients. Institute of Medicine. Learning Objectives
Use caution in the elderly: review of safe and effective medication use in older patients Disclosures I have no disclosures or conflicts of interest related to this presentation John T. Holmes, PharmD,
More informationNational Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL or FAX
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie PRESCRIBING IN THE ELDERLY INTRODUCTION According to the most recent census
More informationNSAIDs Change Package 2017/2018
NSAIDs Change Package 2017/2018 Aim: To Reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care Background A key aim of the Safety in Practice programme is to reduce
More informationPolypharmacy. in the Elderly. Lesley Charles, MBChB, CCFP
Polypharmacy in the Elderly Lesley Charles, MBChB, CCFP Associate Professor and Program Director Division of Care of the Elderly Department of Family Medicine, University of Alberta March 06, 2016 1 Faculty/Presenter
More informationOptimising Safe & Appropriate Medicines Use and Deprescribing. Katie Smith, Director, East Anglia Medicines Information Service February 2014
Optimising Safe & Appropriate Medicines Use and Deprescribing Katie Smith, Director, East Anglia Medicines Information Service February 2014 Background Objectives How & why the OSAMU document was developed
More informationResearch in Real Life. Real Life Effectiveness of Aclidinium Bromide. Version Date: 26 September 2013
Research in Real Life Real Life Effectiveness of Aclidinium Bromide Version Date: 26 September 2013 Project for Almirall Real-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium
More informationDrug use in long term care. Graziano Onder Centro Medicina Invecchiamento Università Cattolica Sacro Cuore, Rome
Drug use in long term care Graziano Onder Centro Medicina Invecchiamento Università Cattolica Sacro Cuore, Rome Polypharmacy in nursing home (USA) Concurrent use of 9 medications was reported for 39.7%
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationRoyal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn
Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Prescribing indicators to assess potentially inappropriate prescribing (PIP): Overview of current criteria and development of the
More informationUse caution in the elderly: review of safe and effective medication use in older patients
Use caution in the elderly: review of safe and effective medication use in older patients John T. Holmes, PharmD, BCPS Assistant Professor of Family Medicine and Pharmacy Practice In support of improving
More informationMajority of drug-related problems identified during medication review are not associated with STOPP/START criteria
Eur J Clin Pharmacol (2015) 71:1255 1262 DOI 10.1007/s00228-015-1908-x PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Majority of drug-related problems identified during medication review are not associated with
More informationInterdisciplinary detection of potential drug related problems in older people
Interdisciplinary detection of potential drug related problems in older people Prof. dr. Mirko Petrovic Department of Internal Medicine, Ghent University Department of Geriatrics, Ghent University Hospital,
More informationIntelligent Polypharmacy. Professor Colin P Bradley Department of General Practice University College Cork
Intelligent Polypharmacy Professor Colin P Bradley Department of General Practice University College Cork Polypharmacy No standard definition 2005 review the use of medications that are not clinically
More informationSurvey of Potentially Inappropriate Prescription Using STOPP/START Criteria in Inha University Hospital
Korean J Fam Med. 2013;34:319-326 http://dx.doi.org/10.4082/kjfm.2013.34.5.319 Survey of Potentially Inappropriate Prescription Using STOPP/START Criteria in Inha University Hospital Original Article Sang-Jin
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationIdentification of medication discrepancies and. potentially inadequate prescriptions in elderly
Identification of medication discrepancies and potentially inadequate prescriptions in elderly adults with polypharmacy Franco Juan Víctor Ariel, MD, Terrasa Sergio MD, MSc, Kopitowski Karin, MD Servicio
More informationStrategies to Decrease Medication Errors in Elderly. Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS
Strategies to Decrease Medication Errors in Elderly Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS Road Map..Outline 1. Introduction A. Definitions B. Geriatrics: High risk population C.
More informationInappropriate Prescribing and Related Hospital Admissions in Frail Older Persons According to the STOPP and START Criteria
Drugs Aging (22) 29:829 837 DOI.7/s4266-2-6- ORIGINAL RESEARCH ARTICLE Inappropriate Prescribing and Related Hospital Admissions in Frail Older Persons According to the STOPP and START Criteria Olivia
More informationPharmaceutical Care for Geriatrics
Continuing Professional Pharmacy Development Program Pharmaceutical Care for Geriatrics Presented by: Alla El-Awaisi; MPharm, MRPharmS, MSc Event Organizer: Dr. Nadir Kheir; PhD Disclaimer: PRESENTING
More information50 years of pharmacovigilance: unfinished job
50 years of pharmacovigilance: unfinished job Joan-Ramon Laporte The role of pharmacoepidemiology in medicines regulation 108 market withdrawals in F, D & UK, 1961-93 Fulminant hepatitis Liver toxicity
More informationAround fifteen semi-structured interviews are going to be conducted with specialist physicians of the domains selected for the checklist.
1 SEMI-STRUCTURED INTERVIEW GUIDE THE INTERVIEW PROCESS This interview is intended to create statements of potential interest for a prescription-screening checklist to detect potentially inappropriate
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationReview Article SUMMARY. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, doi: /jcpt.12059
Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 360 372 doi: 10.1111/jcpt.12059 Review Article of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical,
More informationPolypharmacy and Anticholinergic Burden in Hospitalised Older Patients - A Cross Sectional Audit
INTERNATIONAL JOURNAL of BIOMEDICAL SCIENCE ORIGINAL ARTICLE Polypharmacy and Anticholinergic Burden in Hospitalised Older Patients - A Cross Sectional Audit Joanna Ulley 1, Sakila Sickander 2, Ahmed H.
More informationAll rights reserved. For Permissions, please
Age and Ageing 2008; 37: 673 679 doi: 10.1093/ageing/afn197 Published electronically 1 October 2008 C The Author 2008. Published by Oxford University Press on behalf of the British Geriatrics Society.
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationBriefing Document on Medication use and Falls
Briefing Document on Medication use and Falls This document is intended as a briefing document and is not to be regarded as a document offering definitive legal advice in relation to the subject matter.
More informationTHE ADVANCED MEDICATION REVIEW
THE ADVANCED MEDICATION REVIEW PCNE WORKING SYMPOSIUM ON MEDICATION REVIEW 2009 WORKSHOP 3 Facilitator: Nina Griese n.griese@abda.aponet.de Aim of the workshop 2 To define an advanced medication review
More information1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA
UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE I have no financial conflict of interest to disclose. Lacey Charbonneau, Pharm.D. PGY-1 Community Practice Resident Baptist Medical
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationDeprescribing Unnecessary Medications: A Four-Part Process
Deprescribing Unnecessary Medications: A Four-Part Process Scott Endsley, MD Fam Pract Manag. 2018;25(3):28-32. Abstract and Introduction Introduction www.medscape.com Ms. Horatio is a 76-year-old patient
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationpatients actual drug exposure for every single-day of contribution to monthly cohorts, either before or
SUPPLEMENTAL MATERIAL Methods Monthly cohorts and exposure Exposure to generic or brand-name drugs were captured at an individual level, reflecting each patients actual drug exposure for every single-day
More informationPotentially inappropriate medications in geriatric outpatients. application of six sets of published explicit criteria
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2011.04010.x Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit
More informationcardiovascular risk in elderly people Managing DECISION TO PRESCRIBE keyword: elderlycardio What am I trying to achieve?
Managing cardiovascular risk in elderly people www.bpac.org.nz keyword: elderlycardio DECISION TO PRESCRIBE What am I trying to achieve? Prevent possible future cardiovascular events. Maintain quality
More informationFigure 1. Number of spontaneous reports received by Lareb for the NOACs per year for different sources
1.1. Overview of reports on novel oral anticoagulants (NOACs) Introduction Lareb published overviews of reports concerning the novel anticoagulants (NOACs) apixaban (Eliquis ), dabigatran (Pradaxa ) and
More informationSTART, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy
START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy Jessica DiLeo, PharmD Kate Murphy, PharmD OBJECTIVES Identify pharmacodynamic and pharmacokinetic parameters that may influence treatment
More informationTackling inappropriate polypharmacy in NHS Scotland
Tackling inappropriate polypharmacy in NHS Scotland Francesca Aaen Lead Care Homes Pharmacist - NHS Lanarkshire Heather Harrison - Senior Prescribing Advisor/ Chronic Pain Primary Care Service Development
More informationPitfalls in Pharmacotherapy of Geriatrics
Pitfalls in Pharmacotherapy of Geriatrics DR Ali M. Alyami (M Pharm., PhD) Case Study An 85 year old female with a history of atrial fibrillation, stroke, dementia, and hypertension, who is receiving chronic
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationMEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging
MEDICATION APPROPRIATENESS FOR THE AGING POPULATION Building Partnerships for Successful Aging Learning objectives Appreciate complexities involved in making appropriate clinical decisions in older adults
More informationInternational Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20175209 Original Research Article Geriatric prescription
More informationHealth Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions
Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions Mary Tinetti, M.D. Canadian Geriatrics Society May, 2013 CFPC CoI Templates: Slide 1 Faculty/Presenter
More informationDecision making and medication risk: from signal to policy and regulation. Hubert G. Leufkens UIPS Utrecht Institute for Pharmaceutical Sciences
Decision making and medication risk: from signal to policy and regulation Hubert G. Leufkens Public health effects of medicines Direct clinical effects (e.g. analgesics and pain relief, antivirals and
More informationPolypharmacy: Guidance for Prescribing in Frail Adults
Polypharmacy: Guidance for Prescribing in Frail Adults Why is reviewing polypharmacy important? Medication is by far the most common form of medical intervention. Four out of five people aged over 75 years
More informationRational prescribing in the older adult. Assoc Prof Craig Whitehead
Rational prescribing in the older adult Assoc Prof Craig Whitehead Introduction Physioloical ageing and frailty Medication risks in older adults Drug Burden Anticholinergic and sedative drug burden Cascade
More informationPoliterapia e interazioni negli anziani: possibili interventi
LE ANALISI SULL'USO DEI FARMACI: METODI ED ESPERIENZE IN ITALIA Politerapia e interazioni negli anziani: possibili interventi Graziano Onder Centro Medicina dell Invecchiamento Università Cattolica del
More informationThe Geriatrician in the Trauma Service. Trauma Quality Improvement Program (TQIP) Annual Scientific Meeting and Training 2013
The Geriatrician in the Trauma Service Trauma Quality Improvement Program (TQIP) Annual Scientific Meeting and Training 2013 Challenges of the Geriatric Trauma Patient Challenges of the Geriatric Patient
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationPhysical and Sensory Changes in the Older Adult: Considerations for Medication Management
Physical and Sensory Changes in the Older Adult: Considerations for Medication Management Amber M. Hutchison, PharmD, BCPS Assistant Clinical Professor Auburn University Harrison School of Pharmacy Disclosure/Conflict
More informationPatient Safety in Older Adults
Patient Safety in Older Adults Scott Martin Vouri, PharmD, MSCI, BCPS, BCGP, FASCP St. Louis College of Pharmacy Faculty Disclosure Dr. Vouri is funded by the Washington University Institute of Clinical
More informationHôpitaux Universitaires de Genève
PIM-Check : a new electronic screening tool to detect and manage potentially inappropriate medications in general internal medicine Hôpitaux Universitaires de Genève Anne-Laure Blanc Pharmacienne 1ère
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationPatient Safety in Older Adults
Patient Safety in Older Adults Scott Martin Vouri, PharmD, MSCI, BCPS, BCGP, FASCP St. Louis College of Pharmacy Faculty Disclosure Dr. Vouri is funded by the Washington University Institute of Clinical
More informationPattern of Comorbidities among Colorectal Cancer Patients in Spain
Pattern of Comorbidities among Colorectal Cancer Patients in Spain Miguel Angel Luque-Fernandez, Daniel Redondo-Sánchez, Miguel Rodriguez-Barranco, M Carmen Carmona-Garcia, Rafael Marcos-Gragera, Maria
More informationAppropriate prescribing and deprescribing for older people getting it right. Alan Davis Northland District Health Board
Appropriate prescribing and deprescribing for older people getting it right Alan Davis Northland District Health Board Unused returns Potentially inappropriate medication use in the elderly 15% of older
More informationTOTAL HIP AND KNEE REPLACEMENTS. FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES
TOTAL HIP AND KNEE REPLACEMENTS FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES The Pennsylvania Health Care Cost Containment Council April 2005 Preface This document serves as
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationThe validity of the diagnosis of inflammatory arthritis in a large population-based primary care database
Nielen et al. BMC Family Practice 2013, 14:79 RESEARCH ARTICLE Open Access The validity of the diagnosis of inflammatory arthritis in a large population-based primary care database Markus MJ Nielen 1*,
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationThe contractor establishes and maintains a register of patients with AF
Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently
More informationFollow this and additional works at: Part of the Nursing Commons
Cedarville University DigitalCommons@Cedarville Master of Science in Nursing Theses School of Nursing 8-2013 Retrospective Study to Describe and Compare the Application of Select Sections of the STOPP/
More information< = > less is more. De-diagnosing De-prescribing Non-testing
< = > less is more De-diagnosing De-prescribing Non-testing Who says? Overdiagnosis Polypharmacy False positives Too much medicine Risk aversion $$$ Sources Prof David Le Couteur, Clin Pharm and Aged Care
More informationCover images courtesy of jk1991 at FreeDigitalPhotos.net Infographics courtesy of SIMPATHY consortium
If using any content from this document, please acknowledge the Scottish Government Polypharmacy Model of Care Group, 2018. When referencing this document, please use the following format: Scottish Government
More informationOverview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists
Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationThe development of the PROMPT (PRescribing Optimally in Middle-aged People s Treatments) criteria
Cooper et al. BMC Health Services Research 2014, 14:484 RESEARCH ARTICLE Open Access The development of the PROMPT (PRescribing Optimally in Middle-aged People s Treatments) criteria Janine A Cooper 1,2,
More informationRationalizing Medications. Tan Jianming Senior Pharmacist KTPH
Rationalizing Medications Tan Jianming Senior Pharmacist KTPH + Older patients are more likely to: 2 Have multiple co-morbid diseases Have age-related physiological changes that result in a reduced tolerance
More informationSupplementary Text A. Full search strategy for each of the searched databases
Supplementary Text A. Full search strategy for each of the searched databases MEDLINE: ( diabetes mellitus, type 2 [MeSH Terms] OR type 2 diabetes mellitus [All Fields]) AND ( hypoglycemia [MeSH Terms]
More informationEvidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia
Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia ADI 2018, Chicago FACULTY OF MEDICINE Dr Emily Reeve NHMRC Cognitive Decline
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Svanström H, Pasternak B, Hviid A. Use of azithromycin and
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationZolpidem Is Independently Associated With Increased Risk of Inpatient Falls
ORIGINAL RESEARCH Zolpidem Is Independently Associated With Increased Risk of Inpatient Falls Bhanu Prakash Kolla, MD, MRCPsych 1, Jenna K. Lovely, PharmD, RPh, BCPS 2, Meghna P. Mansukhani, MD 3, Timothy
More information23/11/2018. Tools to stratify patients for clinical pharmacy interventions
Tools to stratify patients for clinical pharmacy interventions Professor Mike Scott Director of the Regional Medicines Optimisation Innovation Centre (MOIC) 47 th ESCP Symposium, Belfast 24 th October
More informationK Barnett, 1 C McCowan, 1 J M M Evans, 2 N D Gillespie, 3 P G Davey, 1 T Fahey 1,4. Error management
< Additional tables are published online only. To view these files please visit the journal online (http:// qualitysafety.bmj.com). 1 Division of Clinical & Population Sciences & Education, University
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationGeri-PARDY! (2015 Beers Criteria) Pharmacology Edition
Geri-PARDY! Pharmacology Edition (2015 Beers Criteria) Aurelio Muyot, MD, AGSF, FACP Assistant Professor College of Osteopathic Medicine Touro University Nevada Objectives Review the 2015 Beers Criteria
More informationUpdate in Geriatrics: Choosing Wisely Primum Non Nocere
Joseph G. Ouslander, M.D. Professor of Clinical Biomedical Science Senior Associate Dean for Geriatric Programs Chair, Department of Integrated Medical Science Charles E. Schmidt College of Medicine Professor
More informationFamily Practice Advance Access published August 8, 2014
Family Practice Advance Access published August 8, 2014 Family Practice, 2014, Vol. 00, No. 00, 1 6 doi:10.1093/fampra/cmu042 Repeat prescriptions of guideline-based secondary prevention medication in
More informationFrom medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist
From medicines reconciliation to medicines review Dr. Fatma Karapinar Hospital pharmacistepidemiologist Conflict of interest Nothing to disclose Questions Medication review is more important than medicines
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More information